Home ETF List About

Portfolio Holdings Detail for ISIN IE00BDZVHG35
Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /var/www/liquidata/show_ticker_holding_ETFs.php on line 77
Stock Name / FundiShares Nasdaq US Biotechnology UCITS ETF USD (Dist)
IssuerBlackrock
ETF TickerBTEE(USD) LSE
ETF TickerBTEE.L(GBP) LSE

Holdings detail for PLRX

Stock NamePliant Therapeutics Inc
TickerPLRX(USD) NASDAQ
TYPECommon Stock
CountryUSA
ISINUS7291391057
LEI5493002Q5LITR7VHZH02

Show aggregate PLRX holdings

News associated with PLRX

Biotech Stocks Rally After-Hours On Trial Updates, Insider Buys, And Conference Buzz
(RTTNews) - Biotech stocks lit up the after-hours session on September 9, 2025, with several small- and mid-cap names posting sharp gains following fresh clinical updates, insider buying, and investor conference appearances. Companies like Immutep, Nautilus Biotechnology, Pliant - 2025-09-10 01:36:37
Analysts Set Pliant Therapeutics, Inc. (NASDAQ:PLRX) PT at $8.19
Pliant Therapeutics, Inc. (NASDAQ:PLRX – Get Free Report) has earned an average recommendation of “Hold” from the thirteen ratings firms that are covering the company, MarketBeat.com reports. Twelve research analysts have rated the stock with a hold recommendation and one has assigned a buy recommendation to the company. The average 12 month target price among […] - 2025-09-05 02:16:53
Comparing Pliant Therapeutics (NASDAQ:PLRX) & CARGO Therapeutics (NASDAQ:CRGX)
Pliant Therapeutics (NASDAQ:PLRX – Get Free Report) and CARGO Therapeutics (NASDAQ:CRGX – Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, profitability, valuation, analyst recommendations, institutional ownership and risk. Profitability This table compares Pliant Therapeutics and […] - 2025-08-15 04:22:53
Federated Hermes Inc. Raises Stock Holdings in Pliant Therapeutics, Inc. (NASDAQ:PLRX)
Federated Hermes Inc. increased its position in Pliant Therapeutics, Inc. (NASDAQ:PLRX – Free Report) by 1,557.6% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 59,209 shares of the company’s stock after acquiring an additional 55,637 shares during the period. Federated Hermes Inc.’s […] - 2025-08-11 04:54:59
Piper Sandler Cuts Pliant Therapeutics (NASDAQ:PLRX) Price Target to $4.00
Pliant Therapeutics (NASDAQ:PLRX – Free Report) had its price objective cut by Piper Sandler from $17.00 to $4.00 in a report published on Friday,Benzinga reports. They currently have an overweight rating on the stock. Pliant Therapeutics Stock Performance NASDAQ:PLRX opened at $1.66 on Friday. The stock has a 50-day simple moving average of $1.44 and […] - 2025-08-11 03:08:44
Pliant Therapeutics, Inc. (NASDAQ:PLRX) Receives $8.19 Consensus Target Price from Brokerages
Pliant Therapeutics, Inc. (NASDAQ:PLRX – Get Free Report) has been assigned an average rating of “Hold” from the thirteen ratings firms that are currently covering the company, Marketbeat reports. Twelve analysts have rated the stock with a hold recommendation and one has assigned a buy recommendation to the company. The average twelve-month price target among […] - 2025-08-11 02:12:52
XTX Topco Ltd Makes New $630,000 Investment in Pliant Therapeutics, Inc. (NASDAQ:PLRX)
XTX Topco Ltd bought a new stake in shares of Pliant Therapeutics, Inc. (NASDAQ:PLRX – Free Report) in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 466,842 shares of the company’s stock, valued at approximately $630,000. XTX Topco Ltd owned about 0.76% of Pliant Therapeutics […] - 2025-08-06 05:17:07
Pliant Therapeutics, Inc. (NASDAQ:PLRX) Given Consensus Recommendation of “Hold” by Analysts
Pliant Therapeutics, Inc. (NASDAQ:PLRX – Get Free Report) has received an average rating of “Hold” from the twelve ratings firms that are covering the company, MarketBeat.com reports. Twelve research analysts have rated the stock with a hold rating. The average twelve-month target price among brokers that have issued ratings on the stock in the last […] - 2025-05-22 02:34:47
Renaissance Technologies LLC Cuts Stock Position in Pliant Therapeutics, Inc. (NASDAQ:PLRX)
Renaissance Technologies LLC lessened its stake in shares of Pliant Therapeutics, Inc. (NASDAQ:PLRX – Free Report) by 72.5% in the 4th quarter, Holdings Channel reports. The firm owned 27,800 shares of the company’s stock after selling 73,400 shares during the period. Renaissance Technologies LLC’s holdings in Pliant Therapeutics were worth $366,000 at the end of […] - 2025-05-05 04:30:58
Pliant Therapeutics, Inc. (NASDAQ:PLRX) Receives $13.31 Consensus PT from Analysts
Shares of Pliant Therapeutics, Inc. (NASDAQ:PLRX – Get Free Report) have earned a consensus recommendation of “Hold” from the twelve ratings firms that are currently covering the firm, Marketbeat reports. Twelve equities research analysts have rated the stock with a hold recommendation. The average twelve-month target price among analysts that have covered the stock in […] - 2025-04-30 02:47:01
Pliant Therapeutics, Inc. (NASDAQ:PLRX) Shares Acquired by Legal & General Group Plc
Legal & General Group Plc increased its holdings in Pliant Therapeutics, Inc. (NASDAQ:PLRX – Free Report) by 21.5% in the fourth quarter, Holdings Channel.com reports. The firm owned 52,961 shares of the company’s stock after purchasing an additional 9,370 shares during the period. Legal & General Group Plc’s holdings in Pliant Therapeutics were worth $697,000 […] - 2025-04-29 05:34:50
American Century Companies Inc. Purchases 9,944 Shares of Pliant Therapeutics, Inc. (NASDAQ:PLRX)
American Century Companies Inc. raised its holdings in shares of Pliant Therapeutics, Inc. (NASDAQ:PLRX – Free Report) by 10.9% during the fourth quarter, Holdings Channel reports. The fund owned 100,849 shares of the company’s stock after buying an additional 9,944 shares during the period. American Century Companies Inc.’s holdings in Pliant Therapeutics were worth $1,328,000 […] - 2025-04-11 04:32:49
HC Wainwright Reaffirms “Neutral” Rating for Pliant Therapeutics (NASDAQ:PLRX)
Pliant Therapeutics (NASDAQ:PLRX – Get Free Report)‘s stock had its “neutral” rating restated by HC Wainwright in a research report issued on Tuesday,Benzinga reports. A number of other research analysts also recently weighed in on PLRX. Citigroup lowered their price target on Pliant Therapeutics from $4.00 to $1.50 and set a “neutral” rating on the […] - 2025-03-20 04:44:46
AlphaQuest LLC Reduces Holdings in Pliant Therapeutics, Inc. (NASDAQ:PLRX)
AlphaQuest LLC lowered its position in Pliant Therapeutics, Inc. (NASDAQ:PLRX – Free Report) by 73.9% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 6,681 shares of the company’s stock after selling 18,890 shares during the quarter. AlphaQuest LLC’s holdings in Pliant […] - 2025-03-19 06:20:56
Wells Fargo & Company Has Lowered Expectations for Pliant Therapeutics (NASDAQ:PLRX) Stock Price
Pliant Therapeutics (NASDAQ:PLRX – Free Report) had its price objective cut by Wells Fargo & Company from $4.00 to $3.00 in a report released on Tuesday morning,Benzinga reports. They currently have an equal weight rating on the stock. Several other brokerages have also recently issued reports on PLRX. Leerink Partners cut Pliant Therapeutics from an […] - 2025-03-07 07:07:07
Pliant Therapeutics (NASDAQ:PLRX) Receives “Neutral” Rating from HC Wainwright
Pliant Therapeutics (NASDAQ:PLRX – Get Free Report)‘s stock had its “neutral” rating reiterated by research analysts at HC Wainwright in a research note issued to investors on Tuesday,Benzinga reports. Several other equities analysts also recently weighed in on the company. JPMorgan Chase & Co. downgraded Pliant Therapeutics from an “overweight” rating to a “neutral” rating […] - 2025-03-06 08:47:03
Royal Bank of Canada Has Lowered Expectations for Pliant Therapeutics (NASDAQ:PLRX) Stock Price
Pliant Therapeutics (NASDAQ:PLRX – Get Free Report) had its price target decreased by equities research analysts at Royal Bank of Canada from $4.00 to $3.00 in a research report issued on Tuesday,Benzinga reports. The firm presently has a “sector perform” rating on the stock. Royal Bank of Canada’s target price indicates a potential upside of […] - 2025-03-06 08:13:24
Pliant Therapeutics (NASDAQ:PLRX) Price Target Cut to $1.50 by Analysts at Citigroup
Pliant Therapeutics (NASDAQ:PLRX – Free Report) had its price objective lowered by Citigroup from $4.00 to $1.50 in a report released on Tuesday morning,Benzinga reports. The brokerage currently has a neutral rating on the stock. PLRX has been the subject of several other reports. Canaccord Genuity Group reissued a “hold” rating and issued a $4.00 […] - 2025-03-05 08:07:38
Pliant Therapeutics (NASDAQ:PLRX) Downgraded to Sector Perform Rating by Royal Bank of Canada
Pliant Therapeutics (NASDAQ:PLRX – Get Free Report) was downgraded by analysts at Royal Bank of Canada from an “outperform” rating to a “sector perform” rating in a report issued on Monday, MarketBeat Ratings reports. They presently have a $4.00 price objective on the stock, down from their prior price objective of $45.00. Royal Bank of […] - 2025-02-12 04:58:57
Pliant Therapeutics (NASDAQ:PLRX) Stock Rating Lowered by HC Wainwright
Pliant Therapeutics (NASDAQ:PLRX – Get Free Report) was downgraded by analysts at HC Wainwright from a “buy” rating to a “neutral” rating in a report issued on Monday, MarketBeat Ratings reports. Pliant Therapeutics Trading Down 15.0 % Shares of Pliant Therapeutics stock opened at $2.61 on Monday. The firm’s 50 day moving average is $12.42 […] - 2025-02-12 04:58:50
Pliant Therapeutics (NASDAQ:PLRX) Stock Rating Lowered by Wells Fargo & Company
Pliant Therapeutics (NASDAQ:PLRX – Get Free Report) was downgraded by Wells Fargo & Company from an “overweight” rating to an “equal weight” rating in a research note issued to investors on Monday, MarketBeat Ratings reports. They presently have a $4.00 price target on the stock, down from their previous price target of $41.00. Wells Fargo […] - 2025-02-12 04:58:50
Pliant Therapeutics (NASDAQ:PLRX) Downgraded to Neutral Rating by Citigroup
Pliant Therapeutics (NASDAQ:PLRX – Get Free Report) was downgraded by investment analysts at Citigroup from a “buy” rating to a “neutral” rating in a note issued to investors on Monday, Marketbeat Ratings reports. They currently have a $4.00 price objective on the stock, down from their prior price objective of $40.00. Citigroup’s target price would […] - 2025-02-12 04:58:48
Pliant Therapeutics Pauses Enrollment And Dosing In BEACON-IPF Trial, Stock In Freefall
(RTTNews) - Pliant Therapeutics Inc. (PLRX) suffered a major blow on Friday, with its shares tumbling nearly 35% in regular trading and plunging another 58% to $3.27 in after-hours, following an update on its BEACON-IPF trial. - 2025-02-10 04:56:26
China Universal Asset Management Co. Ltd. Increases Position in Pliant Therapeutics, Inc. (NASDAQ:PLRX)
China Universal Asset Management Co. Ltd. boosted its holdings in Pliant Therapeutics, Inc. (NASDAQ:PLRX – Free Report) by 10.3% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 12,903 shares of the company’s stock after purchasing an additional 1,209 shares during the quarter. China Universal […] - 2025-02-04 07:15:10
2,490 Shares in Pliant Therapeutics, Inc. (NASDAQ:PLRX) Acquired by R Squared Ltd
R Squared Ltd purchased a new position in shares of Pliant Therapeutics, Inc. (NASDAQ:PLRX – Free Report) in the 4th quarter, Holdings Channel reports. The firm purchased 2,490 shares of the company’s stock, valued at approximately $33,000. Several other institutional investors and hedge funds have also recently bought and sold shares of PLRX. Atria Investments […] - 2025-02-04 06:29:09
Pliant Therapeutics, Inc. (NASDAQ:PLRX) Shares Acquired by SG Americas Securities LLC
SG Americas Securities LLC increased its position in Pliant Therapeutics, Inc. (NASDAQ:PLRX – Free Report) by 27.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 30,729 shares of the company’s stock after buying an additional 6,579 shares during the quarter. SG Americas Securities LLC’s […] - 2025-02-03 06:58:54

iShares Nasdaq US Biotechnology UCITS ETF USD (Dist) PLRX holdings

DateNumber of PLRX Shares HeldBase Market Value of PLRX SharesLocal Market Value of PLRX SharesChange in PLRX Shares HeldChange in PLRX Base ValueCurrent Price per PLRX Share HeldPrevious Price per PLRX Share Held
2025-11-11 (Tuesday)37,399USD 62,456PLRX holding increased by 1870USD 62,4560USD 1,870 USD 1.66999 USD 1.61999
2025-11-10 (Monday)37,399PLRX holding increased by 100USD 60,586PLRX holding increased by 908USD 60,586100USD 908 USD 1.61999 USD 1.59999
2025-11-07 (Friday)37,299USD 59,678PLRX holding increased by 2611USD 59,6780USD 2,611 USD 1.59999 USD 1.52999
2025-11-06 (Thursday)37,299PLRX holding increased by 100USD 57,067PLRX holding decreased by -3939USD 57,067100USD -3,939 USD 1.52999 USD 1.63999
2025-11-05 (Wednesday)37,199USD 61,006PLRX holding increased by 1116USD 61,0060USD 1,116 USD 1.63999 USD 1.60999
2025-11-04 (Tuesday)37,199PLRX holding increased by 100USD 59,890PLRX holding decreased by -2065USD 59,890100USD -2,065 USD 1.60999 USD 1.66999
2025-11-03 (Monday)37,099USD 61,955PLRX holding decreased by -371USD 61,9550USD -371 USD 1.66999 USD 1.67999
2025-10-31 (Friday)37,099USD 62,326PLRX holding increased by 1484USD 62,3260USD 1,484 USD 1.67999 USD 1.63999
2025-10-30 (Thursday)37,099PLRX holding increased by 500USD 60,842PLRX holding decreased by -2840USD 60,842500USD -2,840 USD 1.63999 USD 1.73999
2025-10-29 (Wednesday)36,599PLRX holding increased by 200USD 63,682PLRX holding decreased by -1108USD 63,682200USD -1,108 USD 1.73999 USD 1.77999
2025-10-28 (Tuesday)36,399USD 64,790PLRX holding decreased by -728USD 64,7900USD -728 USD 1.77999 USD 1.79999
2025-10-27 (Monday)36,399USD 65,518PLRX holding decreased by -364USD 65,5180USD -364 USD 1.79999 USD 1.80999
Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdings

Share Trades of PLRX by Blackrock for IE00BDZVHG35

Show aggregate share trades of PLRX

DateActionQuantityMarket HighMarket LowLikely Trade PriceLikely Trade Value (Profit/Loss)Average Price previous trades
2025-11-10BUY1001.6601.560 1.570USD 157 4.59
2025-11-06BUY1001.6551.515 1.529USD 153 4.62
2025-11-04BUY1001.6651.580 1.589USD 159 4.65
2025-10-30BUY5001.7501.630 1.642USD 821 4.70
2025-10-29BUY2001.7401.805 1.798USD 360 4.72
2025-10-22SELL-4001.8101.905 1.895USD -758 4.80 Profit of 1,163 on sale
2025-10-20BUY2001.6401.660 1.658USD 332 4.84
2025-10-17BUY4991.5701.699 1.686USD 841 4.86
2025-10-15BUY7921.5701.580 1.579USD 1,251 4.88
2025-10-03BUY6931.5201.540 1.538USD 1,066 4.92
2025-10-02BUY991.5001.550 1.545USD 153 4.94
2025-09-30BUY1981.4801.505 1.502USD 297 4.98
2025-09-26BUY1981.5201.540 1.538USD 305 5.02
2025-09-25BUY1981.4401.480 1.476USD 292 5.05
2025-09-18BUY991.4901.510 1.508USD 149 5.07
2025-09-17BUY2971.4601.540 1.532USD 455 5.09
2025-07-17SELL-1981.4201.479 1.473USD -292 5.18 Profit of 735 on sale
2025-07-11SELL-8001.4101.425 1.423USD -1,139 5.29 Profit of 3,089 on sale
2025-07-02BUY5,4451.2001.250 1.245USD 6,779 5.39
2025-06-25BUY1981.3801.420 1.416USD 280 5.51
2025-06-11BUY1981.4601.550 1.541USD 305 5.82
2025-06-10BUY1981.5401.650 1.639USD 325 5.85
2025-06-04SELL-991.6601.690 1.687USD -167 5.99 Profit of 426 on sale
2025-04-23BUY991.5401.580 1.576USD 156 7.38
2025-04-10SELL-7921.2551.300 1.295USD -1,026 7.98 Profit of 5,296 on sale
2025-04-08SELL-991.2251.305 1.297USD -128 8.14 Profit of 677 on sale
2025-04-07SELL-991.2501.355 1.345USD -133 8.22 Profit of 680 on sale
2025-04-04SELL-4951.3401.350 1.349USD -668 8.30 Profit of 3,440 on sale
2025-04-01BUY3961.3701.410 1.406USD 557 8.46
2025-03-31SELL-2971.3501.430 1.422USD -422 8.55 Profit of 2,117 on sale
2025-03-14SELL-1,5841.5401.600 1.594USD -2,525 9.63 Profit of 12,734 on sale
2025-03-07SELL-1981.6201.660 1.656USD -328 10.25 Profit of 1,701 on sale
2025-03-04SELL-991.3501.520 1.503USD -149 10.66 Profit of 907 on sale
2025-02-25BUY1983.1703.200 3.197USD 633 11.33
2025-02-19SELL-993.0003.109 3.098USD -307 11.95 Profit of 876 on sale
2025-02-13BUY2973.2903.780 3.731USD 1,108 12.66
2025-02-12BUY992.7202.738 2.736USD 271 12.86
2025-02-11BUY3962.6053.070 3.023USD 1,197 13.08
2024-12-30SELL-2,90112.79013.700 13.609USD -39,480 14.17 Profit of 1,620 on sale
2024-11-18SELL-1,56012.32012.760 12.716USD -19,837 14.56 Profit of 2,882 on sale
2024-11-08SELL-10415.00015.325 15.292USD -1,590 14.58 Loss of -74 on sale
2024-10-21SELL-10514.66015.180 15.128USD -1,588 0.00 Loss of -1,588 on sale
Market high and low price is on the date.

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of PLRX

DateShorted VolumeShort Exempt VolumeTotal Shares Traded% Shorted
2025-09-1997,7710250,24539.1%
2025-09-1874,0290268,01927.6%
2025-09-17166,2980313,17753.1%
2025-09-1649,0480111,10344.1%
2025-09-15106,9945,999187,62557.0%
2025-09-1281,0280166,69848.6%
2025-09-1128,3740197,99014.3%
2025-09-1065,0330154,11142.2%
2025-09-0996,9220284,06234.1%
2025-09-08249,1560562,86944.3%
2025-09-05748,52701,643,55845.5%
2025-09-0417,676063,30927.9%
2025-09-0399,1920398,59524.9%
2025-09-0274,9990233,90732.1%
2025-08-2953,8820340,18015.8%
2025-08-2858,4120253,97423.0%
2025-08-2754,4860371,34414.7%
2025-08-2628,9390467,2386.2%
2025-08-2565,0740683,3069.5%
2025-08-2262,0633,800345,80017.9%
2025-08-2131,1360188,51416.5%
2025-08-2090,7560218,34441.6%
2025-08-1956,134165205,31127.3%
2025-08-1827,3250165,57116.5%
2025-08-1585,1140409,00620.8%
2025-08-1483,2544652,002,4464.2%
2025-08-13126,7501311,280,7659.9%
2025-08-1286,1610372,16123.2%
2025-08-1183,3875,578478,75417.4%
2025-08-0862,40771389,23316.0%
2025-08-0759,53746278,50921.4%
2025-08-06170,0120527,05732.3%
2025-08-0580,9600307,45526.3%
2025-08-04165,8070776,73321.3%
2025-08-01140,6340728,27019.3%
2025-07-3137,3030249,22715.0%
2025-07-3055,7500227,11724.5%
2025-07-2932,218130132,56124.3%
2025-07-28127,5720473,16627.0%
2025-07-2533,6220239,17514.1%
2025-07-2496,7670407,02623.8%
2025-07-23141,10969621,35222.7%
2025-07-22249,92401,169,18021.4%
2025-07-2159,87612,917409,73514.6%
2025-07-1841,053427496,0538.3%

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.